Cadrenal Therapeutics develops a late-stage novel therapy for patients with end-stage renal disease and atrial fibrillation.
Cadrenal Therapeutics has raised $2.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Cadrenal Therapeutics is headquartered in Ponte Vedra Beach, United States.
Cadrenal Therapeutics develops a late-stage novel therapy for patients with end-stage renal disease and atrial fibrillation.
Cadrenal Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cadrenal Therapeutics — Funding & Investors." VCBacked, April 1, 2026, https://www.vcbacked.co/company/cadrenal-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Cadrenal Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cadrenal-therapeutics
{{cite web |title=Cadrenal Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cadrenal-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated